On January 12, the official website of the Yunnan Provincial Health Planning Commission issued the “Notice of the Yunnan Provincial Health and Family Planning Commission on Further Regulating the Management of Clinical Rational Drug Use in Medical Institutions†(“hereinafter referred to as the “Noticeâ€).
The Yunnan Provincial Health Planning Commission stated that the "Notice" is to further standardize the rational use of drugs in medical institutions, consolidate the results of special remediation activities of antibacterial drugs and injectable therapeutic drugs in recent years, optimize the clinical drug application structure of medical institutions, and improve the clinical use of medical institutions. Reasonable application level, effectively curb bacterial resistance, reduce the incidence of adverse drug reactions; effectively control the unreasonable and rapid growth of medical expenses, ensure the safety of medical insurance funds, effectively reduce the burden of medical treatment for the masses; strengthen supervision, resolutely correct the unhealthy trend of the industry; The long-term working mechanism of clinical pharmacy management in medical institutions promotes the continuous improvement of the comprehensive service capacity and management level of clinical pharmacies in medical institutions.
In terms of specific measures, the Yunnan Health Planning Commission requires medical institutions, especially public health institutions at or above the second level, to establish a list of key monitoring drugs (including restricted use and key monitoring), implement dynamic management, and adjust and supplement from time to time.
While establishing a monitoring list of key drugs, all medical institutions must regularly count the use of drugs within medical institutions, and suddenly increase the use of drugs without special causes (such as seasonal diseases, natural disasters, urgently needed drugs, etc.). In the previous cycle of 30%, medical institutions should implement early warning reports on the use of drugs, organize relevant experts, analyze the use of drugs, conduct rational evaluation, promptly intervene, and make announcements within medical institutions.
Medical institutions should provide early warning of prescription or resident medical advice for clinical drug incompatibility rates exceeding 10%. For drugs that have entered the top 20 consumption of the institution for three consecutive months, and the drug disability rate of more than 10% in the third month is included in the restricted use category; if it is restricted use, it should be stopped immediately without special reasons. Used, and cannot be used again during an annual cycle.
At the same time, all medical institutions must strictly implement the dynamic monitoring of prescriptions, analysis and evaluation, public notice, and rectification and rectification system in accordance with the requirements of hospital prescription review management. It is necessary to further expand the scope of prescription reviews, use information technology to play the role of clinical pharmacists, and implement special prescription reviews for drugs that are mainly monitored and drugs that are used for warnings. All medical institutions shall regularly analyze and evaluate the relevant materials such as prescriptions and medical records of the departments and doctors who use the key monitoring drugs, and report the evaluation results. The primary health care institutions are organized by the county-level health and family planning administrative departments, and regular prescription reviews are conducted. The results of the reviews should be linked to the evaluation of the responsible persons, the promotion, and performance appraisal.
Notice of Yunnan Provincial Health and Family Planning Commission on Further Regulating the Management of Clinical Rational Drug Use in Medical Institutions Yunwei Medical Fa [2017] No. 4
State and Municipal Health and Family Planning Commissions, provincial hospitals:
In recent years, in accordance with the unified arrangements of the state, our committee has carried out special rectification activities for the rational application of antibiotics, adjuvant therapeutic drugs for injection, etc., and achieved remarkable results. According to the Central Office and the State Council, “Several Opinions of the Leading Group for Deepening the Reform of the Medical and Health System of the State Council on Further Promoting the Experience of Deepening the Reform of the Medical and Health System†(Dongzi [2016] No. 36) and the State Council “On the Printing and Deepening of the Medical and Health System Reform 2016†Notice of Key Work Tasks of the Year (Guo Dang Fa [2016] No. 26), National Health and Family Planning Commission, Ministry of Finance and other five ministries and commissions "Notice on Printing and Distributing Certain Opinions on Controlling Unreasonable Growth of Medical Expenses in Public Hospitals" (National Health Reform) [2015] No. 89), the National Health and Family Planning Commission, "Notice on Printing and Distributing the Main Points of Correction of Unhealthy Winds in the Purchase and Sale of Medical Products and Medical Services in 2016" (National Health Medical Letter [2016] No. 172), Provincial Government Office The "Notice on Printing and Distributing the Key Tasks for Deepening the Medical and Health System Reform in Yunnan Province in 2016" (Yun Zheng Ban [2016] No. 64) and other documents, combined with the recent problems in the special rectification activities for the rational application of clinical drugs in medical institutions, Consolidate the results of special rectification activities and further standardize the management of clinical rational drug use in medical institutions in our province. The notice of request is as follows:
First, the work target
Further standardize the rational use of drugs in medical institutions, consolidate the results of special remediation activities of antibacterial drugs and injectable therapeutic drugs in recent years, optimize the clinical drug application structure of medical institutions, improve the rational application level of clinical drugs in medical institutions, effectively curb bacterial resistance and reduce The incidence of adverse drug reactions; effective control of unreasonable and excessive growth of medical expenses, ensuring the safety of medical insurance funds, effectively reducing the burden of medical treatment for the masses; strengthening supervision, resolutely correcting the unhealthy trend of the industry; improving the long-term working mechanism of clinical pharmacy management in medical institutions, Promote the comprehensive service capacity and management level of clinical pharmacy services in medical institutions.
Second, the work object
All types of medical institutions at all levels in the province focus on public medical institutions above the second level.
Third, the key content
(1) Establish a key monitoring drug catalogue
All medical institutions shall sort out and analyze the clinical drug use according to the principles of drug safety, effectiveness, economy and application. According to the data related to drug procurement of various medical institutions, combined with the purchase amount, reference price, normal purchase quantity and clinical use, etc. Conduct a comprehensive assessment and establish a hospital key monitoring drug list (including restricted use and key monitoring) and publish it in the medical institution. The catalogue is dynamically managed and is adjusted and supplemented from time to time.
(2) Implementing an early warning system for the abnormal use of drugs
While establishing a monitoring list of key drugs, all medical institutions must regularly count the use of drugs within medical institutions, and suddenly increase the use of drugs without special causes (such as seasonal diseases, natural disasters, urgently needed drugs, etc.). In the previous cycle of 30%, medical institutions should implement early warning reports on the use of drugs, organize relevant experts, analyze the use of drugs, conduct rational evaluation, promptly intervene, and make announcements within medical institutions.
The metal Padlock seals include a fixed-length indicative wire hasp and a plastic locking body. The application of a padlock seals can be : Meters, Doors, Hatches, In-bond Shipments, Bags, Scales,Tankers,Tote Boxes,Trailers, Airline Bar Boxes, Pouches etc.
The Plastic Padlock Seals can be marked by heat stamp or laser engraving. A logo, serial number , barcode , QR code are possible to be personalized on the seals.
The plastic material for the padlock seals can be PP, PC, ABS. The transparent padlock only can use PC material. In order to resist the environment affection, UV additives can be applied to extand the seal life. Or can be a security feature for identification.
Metal Padlock seals,Padlock Wire Seals,Wire Seals,Metal Padlock Seal
Wenzhou Haoshi Light Industrial Products Co., LTD , https://www.economicseals.com